In the BioHarmony Drug Report Database
Semaglutide
Ozempic, Rybelsus, Wegovy (semaglutide) is a protein pharmaceutical. Semaglutide was first approved as Ozempic on 2017-12-05. It has been approved in Europe to treat diabetes mellitus and type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor. Ozempic’s patents are valid until 2038-08-24 (FDA).
Trade Name
|
Ozempic, Rybelsus |
|---|---|
Common Name
|
semaglutide |
ChEMBL ID
|
CHEMBL2108724 |
Indication
|
diabetes mellitus, type 2 diabetes mellitus |
Drug Class
|
Peptides: GLP peptide analogs |
Image (chem structure or protein)